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Diphosphoinositol pentakisphosphate kinase 2
(PPIP5K2) is one of the mammalian PPIP5K isoforms
responsible for synthesis of diphosphoinositol poly-
phosphates (inositol pyrophosphates; PP-InsPs),
regulatory molecules that function at the interface
of cell signaling and organismic homeostasis. The
development of drugs that inhibit PPIP5K2 could
have both experimental and therapeutic applica-
tions. Here, we describe a synthetic strategy for
producing naturally occurring 5-PP-InsP4, as well
as several inositol polyphosphate analogs, and we
study their interactions with PPIP5K2 using
biochemical and structural approaches. These ex-
periments uncover an additional ligand-binding site
on the surface of PPIP5K2, adjacent to the catalytic
pocket. This site facilitates substrate capture from
the bulk phase, prior to transfer into the catalytic
pocket. In addition to demonstrating a ‘‘catch-
and-pass’’ reaction mechanism in a small molecule
kinase, we demonstrate that binding of our analogs
to the substrate capture site inhibits PPIP5K2. This
work suggests that the substrate-binding site offers
new opportunities for targeted drug design.
INTRODUCTION
The process of signal transduction that governs many cellular
activities frequently relies upon evolutionarily conserved fam-
ilies of small, regulatory molecules. Among them are the
diphosphoinositol polyphosphates (inositol pyrophosphates:
5-PP-InsP4, 1-PP-InsP5 [1-InsP7], 5-PP-InsP5 [5-InsP7], and
1,5-[PP]2-InsP4 [InsP8]; Figure 1), in which six to eight phos-
phate groups are crammed around the six-carbon inositol
ring. These high-energy molecules are synthesized by two
distinct classes of kinases, IP6Ks and PPIP5Ks. The IP6Ks
add the 5-diphosphate group (Draskovic et al., 2008); mammals
express three IP6K isoforms (Thomas and Potter, 2014). TheChemistry & Biology 21,PPIP5Ks synthesize the 1-diphosphate (Wang et al., 2012);
there are two isoforms in mammals (Thomas and Potter,
2014). Interest in this field has recently been heightened by
demonstrations that diphosphoinositol polyphosphates operate
at the interface of cell signaling and organismic homeostasis
(Choi et al., 2005; Szijgyarto et al., 2011; Shears, 2009; Illies
et al., 2007; Chakraborty et al., 2010; Pulloor et al., 2014).
Here, a dynamic balance between the activities of IP6Ks and
PPIP5Ks is of particular significance. For example, the syn-
thesis of 5-PP-InsP5 by IP6Ks inhibits the PtdIns(3,4,5)P3/
PDK1/AKT/mechanistic target of rapamycin (mTOR) cascade
(Chakraborty et al., 2010) that controls cell growth and meta-
bolism in response to changes in levels of nutrients, growth
factors, and bioenergetic status (Benjamin et al., 2011). This
inhibitory action of 5-PP-InsP5 is reversed through its further
phosphorylation by the PPIP5Ks (Gokhale et al., 2013). There
may be therapeutic value in inhibiting PPIP5K activity to elevate
5-PP-InsP5 levels and attenuate the mTOR pathway, which is
hyperactivated in 70% of human tumors, contributing to the
derangement of cell growth and metabolism that accompanies
cancer development and progression (Benjamin et al., 2011).
We recently published proof-of-principle of the latter idea by
demonstrating that AKT phosphorylation in myoblasts is in-
hibited when PPIP5K1 expression is ‘‘knocked-down’’ (Gokhale
et al., 2013). It is just such therapeutic motives that frequently
drive the development of drugs that can specifically target ki-
nases such as PPIP5Ks. Candidate molecules may be rationally
designed when information on protein structure is available. To
this end, we recently solved the structure of the N-terminal ki-
nase domain of PPIP5K2 (PPIP5K2KD) in complex with natural
substrate within the catalytic site (Wang et al., 2012). However,
the architecture of the active site exhibits substantial geometric
and electrostatic constraints that raise challenges for the design
of an effective yet specific inhibitor.
In the current study, we set out to prepare substrate analogs
that might modify PPIP5K2 activity. The synthesis of analogs
of diphosphoinositol polyphosphates presents particular
technical challenges due to the reactive nature of the diphos-
phate group and the protected diphosphate intermediates
(Best et al., 2010). The high negative charge density of these
materials also presents purification problems (Capolicchio
et al., 2013). Although several of the naturally occurring689–699, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 689
Figure 1. Biosynthesis of Diphosphoinositol Phosphates
IP5K, inositol pentakisphosphate 2-kinase; IP6K, inositol hexakisphosphate 5-kinase; PPIP5K, diphosphoinositol pentakisphosphate 1-kinase.
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(Albert et al., 1997; Best et al., 2010; Wu et al., 2013; Capolic-
chio et al., 2013), the preparation of useful analogs has only
recently been accomplished (Riley et al., 2012; Wu et al.,
2013). In the latter studies, analogs of 5-PP-InsP4 and 5-PP-
InsP5 were synthesized in which the diphosphate groups
were replaced with metabolically stabilized phosphonoacetate
(PA) or methylenebisphosphonate (PCP) groups. In the current
study, we describe the synthesis of a series of diphosphoinosi-
tol polyphosphate analogs. We demonstrate how we used
these reagents to gain insight into a previously described
(Weaver et al., 2013) substrate-stimulated ATPase activity of
PPIP5K2KD. These experiments also led us to uncover a
second ligand-binding site in PPIP5K2KD that performs an
important aspect of the catalytic cycle by enhancing capture
of substrate from the bulk phase.
RESULTS AND DISCUSSION
Stimulation of the ATPase Activity of PPIP5K2KD by 5-
PA-InsP5 and 2-O-Bn-5-PA-InsP4
We recently reported that PPIP5K2KD exhibits an unusual, non-
productive, substrate-stimulated ATPase activity (e.g., we
observed a 2- to 3-fold activation by 25 mM of either
Ins(1,3,4,5,6)P5 or InsP6; Figure 2A; Weaver et al., 2013). We
now report that 25 mM of either of two previously described
analogs of diphosphoinositol polyphosphates (Riley et al.,
2012) also stimulate ATP hydrolysis 5-fold by 5-O-a-phos-
phonoacetyl-myo-inositol 1,2,3,4,6-pentakisphosphate (5-PA-
InsP5 [1]), and 9-fold by 2-O-benzyl-5-O-a-phosphonoacetyl-
myo-inositol 1,3,4,6-tetrakisphosphate (2-O-Bn-5-PA-InsP4 [2];
Figures 2A and 2B). In view of the precise geometric and electro-
static specificity constraints within the active site (Wang et al.,
2012), we did not anticipate that it could accommodate
2-O-Bn-5-PA-InsP4, which sports a bulky hydrophobic group.
It was therefore unexpected that 2-O-Bn-5-PA-InsP4 should be
a more effective activator of ATPase activity than the two natural
substrates, InsP6 (Figure 2A) and PP-InsP5 (Weaver et al., 2013).
We sought further information on this phenomenon.690 Chemistry & Biology 21, 689–699, May 22, 2014 ª2014 ElsevierDesign and Synthesis of Inositol Phosphate and
Diphosphoinositol Phosphate Analogs
To increase insight into the origin of ligand-stimulated ATPase
activity of PPIP5K2KD, we explored the contributions of the
benzyl (Bn) and a-phosphonoacetyl (PA) groups in 2-O-Bn-
5-PA-InsP4 (2). Our approach was to synthesize a series of
analogs (Figure 2B) that exchanged Bn for either OH, mono-
phosphate, or alternative hydrophobes, whereas the PA group
was replaced by either a monophosphate or a diphosphate.
For analogs containing acyl groups at O-2, the appropriate
synthetic precursors are orthoesters of myo-inositol, because
acid hydrolysis of these compounds gives rise to 2-O-acyl
esters with very high regioselectivity (Godage et al., 2006,
2013). Thus, 2-O-benzoyl-InsP5 (4) and 2-O-butanoyl-InsP5
(5; Figures 2B and 3A) were synthesized from myo-inositol
orthobenzoate (11) and myo-inositol orthobutanoate (12),
respectively. Acid hydrolysis of 11 and 12 (Godage et al.,
2013) gave pentaols 13 and 14, respectively, and subsequent
phosphorylation and deprotection provided 2-O-benzoyl-
InsP5 (4) and 2-O-butanoyl-InsP5 (5).
For analogs containing alkyl ethers or hydroxyl groups at
C-2, synthetic routes proceeding from the symmetrical
butane-2,3-diacetal (BDA) protected diol 17 are expedient, as
in our recent synthesis of 2-O-(2-aminoethyl)-InsP5 (6; Riley
et al., 2014). The remaining compounds 7–10 were also syn-
thesized from diol 17 using a unified approach (Figures 2B
and 3B). Thus, regioselective benzylation of the axial hydroxyl
group of diol 17 gave 2-O-benzyl ether 18, and removal of
BDA protecting groups gave pentaol 19. Phosphorylation of
19 afforded the symmetrical pentakisphosphate 20 and
cleavage of phosphate protection gave 2-O-Bn-InsP5 (7) in
59% overall yield from 17.
For the synthesis of 2-O-Bn-5-PP-InsP4 (8) and 5-PP-InsP4 (9),
the C-5 hydroxyl group of 18 was first phosphitylated with
bis(cyanoethyl)(N,N-diisopropylamino)phosphine, followed by
oxidation to provide the protected monophosphate 21. Removal
of BDA groups followed by phosphorylation afforded the fully
protected pentakisphosphate 23 in high yield (Figure 3B). We
constructed the diphosphate group by modifying a recentlyLtd All rights reserved
Figure 2. The Effects of Inositol Phosphates and Analogs upon ATPase Activity of PPIP5K2KD
(A) The effects of the indicated inositol phosphates and analogs (25 mM) upon ATPase activity of PPIP5K2KD. Data represent means and SEs from three ex-
periments. Data for Ins(1,2,3,4,5)P5 (InsP5) and InsP6 are taken from Weaver et al., 2013.
(B) The structures of the reagents that were used.
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was treated with DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) and
BSTFA (N,O-bis(trimethylsilyl)trifluoroacetamide) to remove both
cyanoethyl protecting groups on the 5-phosphate, followed by
methanolysis of the temporary trimethylsilyl protection to give
the phosphate monoester at the C-5 position. Phosphitylation
then afforded a mixed P(III)-P(V) intermediate, which was
oxidized to produce 24 (Figure 3B). We next prepared 2-O-Bn-
5-PP-InsP4 (8) from crude 24 (which contained DBU), by hydro-Chemistry & Biology 21,genolysis over palladium hydroxide, which removed the benzyl
esters from the phosphates; amines (either in DBU or in triethyl-
amine; Riley et al., 2012) inhibit hydrogenolytic cleavage of the
2-O-benzyl ether. Note that 2-O-Bn-5-PP-InsP4 (8) is a synthetic
analog of an inositol pyrophosphate that retains the actual
diphosphate group.
Hydrogenolysis of purified 24 from which DBU was removed
yielded 5-PP-InsP4 (9), in 51% overall yield from 23 (Figure 3B).
This molecule is a naturally occurring diphosphoinositol689–699, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 691
Figure 3. Chemical Syntheses
(A) Syntheses of 2-O-Bz-InsP5 (4) and 2-O-But-InsP5 (5).
(B) Syntheses of 2-O-Bn-InsP5(7), 2-O-Bn-5-PP-InsP4 (8), 5-PP-InsP4 (9), and 2,5-di-O-Bn-InsP4 (10). Reagents and conditions: (a) TFA:H2O, 10:1; (b)
(BnO)2PN(
iPr)2, 5-phenyl-1-H-tetrazole, DCM; (c)mCPBA,40C to room temperature; (d) Pd(OH)2, H2, MeOH, H2O; (e) BnBr, NaH, DMF; (f) aq TFA (90%):DCM,
1:1; (g) (NCCH2CH2O)2PN(
iPr)2, 5-phenyl-1-H-tetrazole, DCM; (h) tBuOOH,40C to room temperature; (i) aq ammonia, 70C; (j) DBU, BSTFA; (k) MeOH, TFA; (l)
NaHCO3, Pd(OH)2, H2,
tBuOH, H2O.
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(Figure 1); 5-PP-InsP4 has been implicated in telomere mainte-
nance (York et al., 2005; Saiardi et al., 2005). Finally, for the syn-
thesis of 2,5-di-O-Bn-InsP4 (10), diol 17was benzylated followed
by cleavage of BDA groups. Subsequent phosphorylation and
deprotection of cyanoethyl phosphate esters gave (10) in 63%
overall yield from 17 (Figure 3B).
Stimulation of the ATPase Activity of PPIP5K2KD by
Synthetic Inositol Phosphate Analogs
As discussed above (see also Figure 2A), 2-O-Bn-5-PA-InsP4 (2)
strongly activated nonproductive ATPase activity of PPIP5K2KD.
The degree of stimulation was dramatically reduced when the
latter’s benzyl group was replaced with a hydroxyl group to
give 5-PA-InsP4 (3, the PA analog of 5-PP-InsP4; Riley et al.,
2012; Figure 2). Furthermore, 5-PP-InsP4 (9) stimulated
ATPase activity at about half the rate shown by 2-O-Bn-5-PP-
InsP4 (8). Taken together, these data (Figure 2) lead to an unex-
pected conclusion that the ligand’s benzyl group makes an
important contribution to its association with PPIP5K2KD.
In 2-O-Bn-5-PP-InsP4 (8), the natural and more negatively
charged diphosphate (PP) group replaces the PA group at O-5
in 2-O-Bn-5-PA-InsP4 (2). We found that 2-O-Bn-5-PP-InsP4
(8) was slightly (20%) more effective at stimulating ATPase activ-
ity than was 2-O-Bn-5-PA-IP4 (2; Figure 2). Nevertheless, the PA
group still contributes to efficacy more than a monophosphate
group because 2-O-Bn-InsP5 (7) was less effective than was
2-O-Bn-5-PA-InsP4 (2; Figure 2).
Even in 2-O-Bn-InsP5 (7), the 2-O-benzyl ether has an
enhancing effect, roughly doubling the rate of ATP hydrolysis
that is induced by InsP6, which has a phosphate group at C-2
(Figure 2). To investigate the effect of hydrophobes other than
benzyl at O-2, we compared 2-O-Bn-InsP5 (7) with 2-O-Bz-
InsP5 (4) and 2-O-But-InsP5 (5). The change from the 2-O-benzyl
ether to the structurally related 2-O-benzoyl ester led to only a
minimal reduction in ATPase-stimulating activity, while substitu-
tion with a 2-O-butanoyl ester gave a sharp reduction in activity
(Figure 2). Furthermore, the analog with a positively charged
aminoethyl group at O-2 in (2-O-AminoEt-InsP5 [6]) did not stim-
ulate ATPase activity (Figure 2).
We next tested one further analog in which the diphosphate
group in 2-O-Bn-5-PP-InsP4 (8) was replaced with a second
benzyl group (i.e., 2,5-di-O-Bn-InsP4; 10). This compound
elicited the highest degree of ATPase activity among all of the
analogs that we have synthesized (Figure 2). This was initially a
puzzling conclusion, as structural considerations indicate that
2,5-di-O-Bn-InsP4 (10) would at best be a poor ligand for the
active site.
Several of the compounds described above were selected
for detailed dose-response curves; we used the six compounds
that yielded the greatest stimulation of ATPase activity, with
the exception of 2-O-Bz-InsP5 (4), which in any case showed
similar efficacy to 2-O-Bn-InsP5 (7; Figure 4A). The most
potent of this series of compounds was 2,5-di-O-Bn-InsP4 (10,
half-maximal effective concentration [EC50] = 340 nM; Figure 4A).
In general, the rank order of the EC50 values for these
compounds approximated the rank order of their maximal
effects, with the notable exception of 2-O-Bn-5-PP-InsP4 (8;
Figure 4A).Chemistry & Biology 21,Inhibition of PPIP5K2KD Catalytic Activity by Inositol
Phosphate Analogs
The six compounds that were selected for the dose-response
curves in the assays of ATP hydrolysis (Figure 4A) were now
investigated for their effects upon diphosphoinositol poly-
phosphate metabolism by PPIP5K2KD (Figure 4B). We used
a high-throughput reverse-kinase assay that records ATP
generated from ADP during the dephosphorylation of 100 nM
1,5-[PP]2-InsP4 (Riley et al., 2012; Weaver et al., 2013). Each of
the tested analogs inhibited [PP]2-InsP4 metabolism by
PPIP5K2KD (Figure 4B). The two most potent of these analogs
were 5-PA-InsP5 (1) and 2,5-di-O-Bn-InsP4 (10) (Figure 4B).
The inhibitory effect of 5-PA-InsP5 (1) was not in itself surprising
becasue we have already demonstrated it to be a PPIP5K sub-
strate (Riley et al., 2012). However, the inhibition by 2,5-di-O-
Bn-InsP4 (10) was more unexpected because due to its bulk,
and its less negative charge compared to physiological sub-
strates, we predict it to be a poor ligand for the active site of
the highly specific PPIP5K2KD (Wang et al., 2012). Nevertheless,
its ability to inhibit reverse-kinase activity was directly confirmed
by high-performance liquid chromatography (HPLC) analysis of
[PP]2-[
3H]InsP4 dephosphorylation (Figures S1A–S1C available
online). We confirmed that 2,5-di-O-Bn-InsP4 (10) also inhibited
PPIP5K2KD in the ‘‘forward,’’ kinase direction using InsP6, a
physiologically relevant substrate (Figures S1D and S1E). A
Dixon plot demonstrated that inhibition by 2,5-di-O-Bn-InsP4
(10) was competitive in nature (Ki = 240 nM; Figure 4C), arguing
that its actions are not allosteric in nature.
The rank order of potencies (as half-maximal inhibitory con-
centration [IC50] values) with which this group of molecules in-
hibited [PP]2-InsP4 dephosphorylation by PPIP5K2
KD (Figure 4B)
is different in two key respects from the rank-order of efficacy
(EC50 values) for their separate stimulation of ATPase activity
(Figures 4A and 4B). First, 2-O-Bn-InsP5 (7) is 4-fold less potent
than 2-O-Bn-5-PA-InsP4 (2) at stimulating ATPase activity (Fig-
ure 4A), whereas the two analogs are equally efficient at inhibit-
ing [PP]2-InsP4 metabolism (Figure 4B). Second, 5-PA-InsP5 (1),
the weakest activator of ATPase (Figure 4A), is the most potent
inhibitor of [PP]2-InsP4 dephosphorylation (Figure 4B). These
are observations that suggest there is some uncoupling of
inositol phosphate turnover from the ATPase activity.
Structural Analysis Reveals that PPIP5K2KD Has Two
Adjacent Ligand-Binding Sites
We have previously published an atomic-level description of
both 5-PP-InsP5 and InsP6 substrates bound into the catalytic
pocket of PPIP5K2KD (Wang et al., 2012). In a separate study,
we (Riley et al., 2012) soaked 2 mM 5-PA-InsP5 (1) into crystals
of PPIP5K2KD, and reported that this ligand occupies the active
site in the same orientation as the natural substrate. At the time of
that earlier study, we contoured the simulated annealing omit
map at 2 s, and observed some additional but uninterpretable
electron density at the entrance of the active site (data not
shown). For the current study, we increased the soaking concen-
tration of 5-PA-InsP5 (1) to 10 mM, and have now unequivocally
detected an additional ligand-binding site, at 1.7 A˚ resolution,
that is located near the surface of PPIP5K2KD, at the entrance
to the catalytic center (Figures 5A and 5D; Table S1). This
surface-mounted ligand-binding site is too remote from ATP to689–699, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 693
Figure 4. Effects of Inositol Phosphate Ana-
logs upon PPIP5K2KD Activities: ATPase,
1,5-[PP]2-InsP4 Dephosphorylation and
InsP6 Phosphorylation
(A and B) Dose-response curves are shown for the
indicated inositol phosphate analogs and their
stimulation of ATPase activities (A), and their
inhibition of ADP-driven dephosphorylation of
100 nM [PP]2-InsP4 (B). Error bars represent SEs
(n = 3). The EC50 and IC50 values for the molecules
tested are given in the key to the right of (A) and (B).
(C) A Dixon plot of the inhibition of InsP6 kinase
activity of PPIP5K2KD by 2,5-di-O-Bn-InsP4 (10);
the data are from a representative experiment (one
of three), performed in duplicate. Insets illustrate
the reaction being assayed.
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site and the catalytic pocket cannot be occupied simultaneously
due to steric clashing (Figures 5A and S2A). That is, these
particular structural data arise from a mixture of crystal com-
plexes in which 5-PA-InsP5 (1) is separately bound to either of
the two sites.
The stimulation of ATPase activity of PPIP5K2KD by either 2-O-
Bn-5-PA-InsP4 (2) or 2,5-di-O-Bn-InsP4 (10) indicates that these
compounds also interact with PPIP5K2KD, so we soaked694 Chemistry & Biology 21, 689–699, May 22, 2014 ª2014 Elsevier Ltd All rights reserved5–10 mM of either 2-O-Bn-5-PA-InsP4
(2) or 2,5-di-O-Bn-InsP4 (10) into the
PPIP5K2KD crystals. X-ray analysis re-
vealed that both of these analogs were
exclusively associated with the second
ligand-binding site (Figures 5B, 5C, 5E,
and 5F; Table S1). Neither of these ana-
logs was found to occupy the catalytic
site. These data suggest that the stimula-
tion of ATPase activity by either natural
substrates or their analogs is associated
with their occupation of the second bind-
ing site, not the catalytic site. That expla-
nation is in turn consistent with other data
(Figures 4A and 4B, and see above) that
suggest ligand-stimulated ATPase activ-
ity is uncoupled from the inositol phos-
phate kinase activity.
The architecture of this second ligand-
binding site is represented by a deep
cleft, which is walled on one side by
K53, K54, and K103. The opposite face
is formed from R213, and a loop created
from residues E192 to H194 (Figure 5).
In this binding site, the shared groups in
5-PA-InsP5 (1) and 2-O-Bn-5-PA-InsP4
(2) exhibit almost identical conformations
(Figure 6A). As for 2,5-di-O-Bn-InsP4 (10)
this molecule is rotated 20 clockwise
(Figure 6B). For both 2-O-Bn-5-PA-InsP4
(2) and 2,5-di-O-Bn-InsP4 (10), their
phosphate groups at C-3 and C-4 would
clash with the positions that the C-4 andC-3 phosphates of InsP6/5-PP-InsP5 normally occupy in the
active site (Figures S2A–S2C). This phenomenon presumably
contributes to the potency of both 2-O-Bn-5-PA-InsP4 (2) and
2,5-di-O-Bn-InsP4 (10) as inhibitors of inositol phosphate
turnover by PPIP5K2KD (Figures 4B and 4C). These structural
considerations explain how both compounds can inhibit inositol
phosphate kinase activity without occupying the catalytic site.
The association of 2-O-Bn-5-PA-InsP4 (2) and 2,5-di-O-Bn-
InsP4 (10) with the second binding site is facilitated by their
Figure 5. X-Ray Analysis of Inositol Phosphate Analogs Bound to PPIP5K2KD Uncovers Two Ligand-Binding Sites
X-ray analysis was performed after we soaked crystals of PPIP5K2KD with either 10 mM of 5-PA-InsP5 (1), 5 mM of 2-O-Bn-5-PA-InsP4 (2), or 10 mM of 2,5-di-O-
Bn-InsP4 (10).
(A–C) Surface representations of ligand binding, with the analogs shown as stick-and-ball models. Atoms are blue for nitrogen; red for oxygen; orange for
phosphorus; and gray, cyan or green for carbon.
(D–F) The corresponding depictions of the protein as a ribbon diagram, with some key residues as stick models and numbered. For increased clarity, (D) only
shows the 5-PA-InsP5 (1) that binds to the capture site (see the text for the functional rationalization of this site). The carbons around the inositol ring are
numbered. AMPPNP is brown and magnesium atoms are magenta. Refined 2Fo-Fc maps are contoured at 1.0 s and are shown in gray mesh.
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interactions with K53, K54, and R213 (Figures 5, S2E, and S2F).
The terminal phosphonate of 2-O-Bn-5-PA-InsP4 (2) also forms
polar contacts with the backbone of K103 and the H194 side
chains (Figures 5 and S2E). Additionally, the 5-O-benzyl group
in 2,5-di-O-Bn-InsP4 (10) has van der Waals interactions with
the side chains of H101 and E192 (Figures 5 and S2F). The 2-
O-benzyl group in this analog is disordered, indicative of its
mobility. Nevertheless, our catalytic data (Figure 4) indicate
that this benzyl group makes a significant contribution to ligand
potency.
The data that we have obtained allow important conclusions
to be drawn concerning the likely significance of the second
binding site. For example, we can exclude the possibility that,
as is the case with certain enzymes (Reed et al., 2010), the
role of the second, noncatalytic substrate-binding site is to
regulate enzyme activity by substrate inhibition; PPIP5K2KD
does not exhibit that property (Weaver et al., 2013). Other
enzymes use noncatalytic ligand-binding sites to promote
enzyme activation allosterically (Grant, 2012). That also seems
unlikely to be the case for PPIP5K2KD, because our inositol
phosphate analogs do not enhance kinase activity, but inhibit
it instead (Figure 4B; Riley et al., 2012). The nature of the inhi-Chemistry & Biology 21,bition was competitive (Figure 4C), further arguing against
an allosteric effect. Instead, the proximity to the active site
of the second ligand-binding site (Figure 4) suggests that the
latter plays a role in catalysis of natural substrates, by facili-
tating their capture from the bulk phase. A precedent for
such a phenomenon has been reported for microbial anthrani-
late phosphoribosyltransferases (Castell et al., 2013; Marino
et al., 2006); anthranilate substrate is first captured at a sur-
face-mounted binding-site, before delivery to a proximal cata-
lytic site (Castell et al., 2013). A similar substrate transfer is
feasible in PPIP5K2KD, and our structural data provide some
atomic-level insight into such a phenomenon. For example,
we presume that delivery of natural substrate is efficient, so
that substrate only occupies the capture site transiently; this
may explain why we could not detect substrate in the capture
site in our crystal structures. We found that such substrate
transfer within PPIP5K2KD requires that the inositol ring be flip-
ped and rotated by 100 (Figures 6D and 6E). This motion is
presumably facilitated by the flexible amino-acid side chains
that comprise the active site (Wang et al., 2012). Such confor-
mational dynamics can reinforce catalytic specificity (Hers-
chlag, 1988), which is indeed a notable feature of PPIP5K2KD
(Wang et al., 2012).689–699, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 695
Figure 6. Relative Orientations of Inositol
Phosphate Analogs in the Second Ligand-
Binding Site of PPIP5K2KD
Data for ligand orientation in the second binding
site were obtained as described in Figure 5.
Analogs are depicted as stick models. Atoms are
blue for nitrogen, red for oxygen, and orange for
phosphorus.
(A) Superimposition of 5-PA-InsP5 (1; carbons in
gray) and 2-O-Bn-5-PA-InsP4 (2; carbons in cyan).
(B and C) Superimposition of 2,5-di-O-Bn-InsP4
(10; carbons in green) and 2-O-Bn-5-PA-InsP4 (2;
carbons in cyan). Arrows in (B) emphasize spatial
separation, and (C) includes details of ligand in-
teractions with neighboring amino acid residues.
(D and E) illustrate that transfer of 5-PA-InsP5 (1)
between the two sites involves a lateral migration
of 7 A˚, a ring flip, and a rotation of 100. Atoms
are blue for nitrogen, red for oxygen, orange for
phosphorus, and gray for carbon. The inositol ring
is numbered.
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A PPIP5K Substrate Capture SiteSite-Directed Mutagenesis of the Substrate Capture
Site
Mutagenesis offers a valuable means of pursuing conclusions
drawn from structural analysis. The loop that is formed from res-
idues A191 to H194 screens the catalytic site from ligands that
are associated with the second binding site (Figures 5, 7A, and
S3). The influence of the carbonyl oxygen of A191 may be indi-
rect, through a hydrogen bond with a water molecule that in
turn coordinates with an Mg2+ ion that interacts with the nucleo-
tide’s b-phosphate moiety (Figure 7A). The role of H194 seems
more direct; it can form a hydrogen bond with the oxygen
atom of the nucleotide’s b-phosphate (Figures 7A and S3). This
could stabilize the transition state, or have some other catalytic
role. These interactions could be relevant to both kinase and
ATPase activities of PPIP5K2KD. Consistent with these ideas,
an H194A mutant did not exhibit any detectable ATPase activity,
either in the presence or absence of 2-O-Bn-5-PA-InsP4 (2) or
2,5-di-O-Bn-InsP4 (10), and its inositol phosphate kinase activity
was reduced 80-fold compared to that of the wild-type enzyme
(data not shown).
As discussed above, our structural and biochemical data led
us to hypothesize that the stimulation of ATPase activity by
either natural substrates or their analogs is associated with
their occupation of the substrate capture site, not the catalytic
site. We attempted to consolidate this idea by selecting for
mutation residues that might separate ATPase activity from
inositol phosphate kinase activity. For example, our X-ray
data (Figure 5) indicate that K54 and R213 interact with ligand
at the substrate capture site. However, previous mutagenic
work has shown that both K54 and R213 also contribute
directly to inositol phosphate kinase activity (Wang et al.,
2012). Nevertheless, we did observe that K54A and R213A
mutants exhibited a substantially impaired degree of stimula-
tion of ATPase activity by either 2-O-Bn-5-PA-InsP4 (2) or696 Chemistry & Biology 21, 689–699, May 22, 2014 ª2014 Elsevier Ltd All rights reserved2,5-di-O-Bn-InsP4 (10) (Figures 7B and
7C). These mutagenic data are consis-
tent with the idea that K54 and R213
participate in substrate capture.The side chain of K103 is also suggested by our structural data
to interact with ligand that is bound to the capture site (Figures 5
and S2). Nevertheless, a K103A mutant showed only a slight
reduction in 2-O-Bn-5-PA-InsP4 (2)-activated and 2,5-di-O-Bn-
InsP4 (10)-activated ATPase activity, compared to wild-type
enzyme (Figures 7B and 7C). Likewise, the InsP6 kinase activity
of the K103A mutant (71 ± 4 nmol/mg protein/min, n = 3) was
similar to that of wild-type enzyme (61 ± 4 nmol/mg protein/min).
We also mutated E192. This residue is present in the loop
between the two ligand-binding sites (Figure 7A). It is too distant
from ATP and the catalytic site to influence either directly, and
electrostatic repulsion would prevent it from interacting with
negatively charged groups on substrates located in the second
binding site. Nevertheless, E192 is evolutionarily conserved in
PPIP5Ks from mammals to yeast (not shown), suggestive of
functional significance. We investigated the significance of
E192 by preparing E192G and E192Q mutations that we posited
would eliminate electrostatic repulsion between the amino acid
side chain and phosphorylated ligands, enhancing ligand bind-
ing to the substrate capture site. We further hypothesized that
such an effectmight reduce the efficiency of transfer of substrate
to the catalytic site, which in turn would lead to a reduction in
inositol phosphate kinase activity. Indeed, we found that these
E192G and E192Q mutations reduced the rate of InsP6 phos-
phorylation by 12- and 18-fold respectively, compared to wild-
type PIP5K2KD (Figure 7D). It was of further note that neither of
these particular mutations altered the rate of nonproductive,
ligand-stimulated ATPase activity elicited by either 2-O-Bn-
5-PA-InsP4 (2), 2-O-Bn-5-PP-InsP4 (8), or 2,5-di-O-Bn-InsP4
(10; Figure 7E), confirming the uncoupling of this aspect of
PPIP5K2KD activity from its kinase activity.
We have shown that 2,5-di-O-Bn-InsP4 (10) binds to a sub-
strate-capture site on the surface of PPIP5K2KD (Figure 5),
thereby inhibiting the enzyme’s catalytic activity (Figure 4). This
Figure 7. Impact on the Catalytic Properties of PPIP5K2KD Following Mutation of K54, K103, E192, and K213
(A) The spatial separation of AMPPNP from the PPIP5K2KD substrate capture site. Protein residues are shown as stick models. AMPPNP, and inositol phosphate
analogs 5-PA-InsP5 (1), 2-O-Bn-5-PA-InsP4 (2), and 2,5-di-O-Bn-InsP4 (10) and all are shown as stick models. Atoms are blue for nitrogen; red for oxygen; orange
for phosphorus; and gray, cyan, or green for carbon. Hydrogen bonds are shown as black dashed lines.
(B and C) Dose-response curves for the effects of 2-O-Bn-5-PA-InsP4 (2) and 2,5-di-O-Bn-InsP4 (10) upon the ATPase activities of wild-type PPIP5K2
KD (closed
circles; data are taken from Figure 2A) and the following mutants: K54A mutant (closed squares), K103A (open circles), and R213A (open squares).
(D) The InsP6 kinase activities of wild-type, E192G, and E192Q mutants of PPIP5K2
KD, determined with 5 mM substrate.
(E) The ATPase activities of wild-type and E192Qmutants of PPIP5K2KD obtained in the presence of the indicated analogs, at concentrations of 25 mM. Error bars
represent SEs from three experiments (error bars are not shown when they are smaller than the symbol).
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A PPIP5K Substrate Capture Siteparticular ligand-binding site may be exploitable as a pharmaco-
logical target. We therefore examined the specificity of 2,5-di-O-
Bn-InsP4 (10) by investigating if it interacted with IP6K2, a
member of a different class of kinases that also phosphorylate
InsP6 and synthesize diphosphoinositol polyphosphates (see
Figure 1). Because the affinity of IP6K2 for InsP6 (430 nM; Saiardi
et al., 2000) is very similar to that for InsP6 phosphorylation by
PPIP5K2KD (390 nM; Weaver et al., 2013), an identical substrate
concentration ([InsP6] = 500 nM) was used to assay both
enzymes. As shown in Figure 4C, 2,5-di-O-Bn-InsP4 (10) inhibits
PPIP5K2KD with an IC50 value of 1 mM (Figure 4C). This analog
was found to be a much weaker inhibitor of IP6K2 activity
(IC50 = 63 mM; data not shown). Thus, 2,5-di-O-Bn-InsP4 (10)
may be a useful lead molecule for future development of a
drug that can specifically inhibit PPIP5Ks and not IP6Ks, even
though both groups of enzymes phosphorylate InsP6.Chemistry & Biology 21,In conclusion, our studies have uncovered a ‘‘catch-and-
pass’’ aspect to the catalytic cycle of PPIP5K2KD. Substrate
(either InsP6 or 5-PP-InsP5) first associates with a ligand-
binding site on the surface of the kinase. We propose that
this phenomenon enhances kinase activity by improving sub-
strate capture from the bulk phase; substrate is then delivered
into the catalytic pocket. We are not aware of any other exam-
ples of a substrate-capture mechanism in a small-molecule
kinase. Indeed, the only example that we have found in the
literature for a dedicated substrate capture site on any enzyme
is that observed for certain microbial anthranilate phosphoribo-
syl-transferases (Castell et al., 2013; Marino et al., 2006). Our
structural, biochemical, and mutagenic data have also led us
to conclude that the stimulation of ATPase activity of PPIP5K
by inositol phosphate analogs is associated with their occu-
pation of the substrate capture site, not the catalytic site.689–699, May 22, 2014 ª2014 Elsevier Ltd All rights reserved 697
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A PPIP5K Substrate Capture SiteMoreover, the previously puzzling observation (Weaver et al.,
2013) that a degree of nonproductive ATP hydrolysis is also
stimulated by natural substrate, can now be rationalized as a
consequence of its interaction with the capture site. Further-
more, the fact that InsP6-stimulated ATPase activity is abol-
ished by an R213A mutation (Weaver et al., 2013) can now
be viewed as resulting from an impairment to substrate occu-
pation of the capture site.
Our atomic-level description of the substrate-capture site
on PPIP5K2KD indicates its structural determinants of specificity
differ substantially from those of the catalytic site. We have
further shown that synthesis of diphosphoinositol polyphos-
phates by PPIP5K2KD is inhibited by ligands that bind to the cap-
ture site but not the catalytic site. These findings in turn raise the
possibility that there may be cellular constituents that might
inhibit catalytic activity by binding to this site. Finally, the sub-
strate capture site offers a selective target for the purposes of
rational drug design, including screening in silico (Kitchen
et al., 2004), that is free from many of the usual specificity con-
straints within the catalytic site that typically complicate pharma-
cological targeting of small-molecule kinases. It may also be
possible to design a ligand that occupies both sites.
SIGNIFICANCE
PPIP5K1 and PPIP5K2 are small-molecule kinases that
synthesize diphosphoinositol polyphosphates, which func-
tion at the interface of cell signaling and organismic homeo-
stasis. Synthetic chemical modulators of cell-signaling
enzymes such as the PPIP5Ks can provide valuable insight
into catalytic mechanisms, they decipher the biological
roles of the enzymes in situ, and they generate leads for
therapeutic drug development. Substrate analogs offer
one approach for the preparation of such chemical reagents.
However, the architecture of the active site of PPIP5Ks, as
revealed by recent X-ray analysis, has identified substantial
geometric and electrostatic constraints that limit the
options for designing a substrate analog that might be an
effective modulator. In the current study, we describe the
chemical synthesis of both the naturally occurring 5-
PP-InsP4 and a family of inositol polyphosphate analogs
that include molecules with hydrophobes at the 2- and/or
5-positions. Importantly, these molecules have led us to
characterize a second, less constrained substrate-binding
site on the surface of PPIP5K2, adjacent to the catalytic
pocket. We provide an atomic-level description of this sur-
face-mounted site and describe its role in the catalytic cycle
in capturing substrate from the bulk phase. With the assis-
tance of site-directed mutagenesis of this site, we show
that its occupation is associated with an unusual, ligand-
activated ATPase activity. This considerable amount of
information had not been accessible with our experiments
with natural substrates and represents a success for our
chemical biology approach. In addition to adding to
the repertoire of catalytic specializations of the PPIP5Ks,
our structural and functional characterization of this
ligand-binding site offers a promising target for drug devel-
opment; to this end, 2,5-di-O-Bn-InsP4 is a significant lead
compound.698 Chemistry & Biology 21, 689–699, May 22, 2014 ª2014 ElsevierEXPERIMENTAL PROCEDURES
Protein Expression, Purification, Crystallization, and Structure
Determination
The kinase domain of human PPIP5K2 (PPIP5K2KD; residues 1–366) and the
N-terminally truncated domain used for the crystallography studies (residues
41–366)weresubcloned,expressed,andpurifiedasbefore. The latterwascrys-
tallized by hanging drop vapor diffusion against a well buffer of 12% (w/v) PEG
3350, 20mMMgCl2, 0.1MHEPES, pH7.0, 1mMAMP-PNP, and 2mMCdCl2 at
4C. The crystals were then soaked with 5–10 mM compounds in a stabilizing
buffer containing 22% (w/v) PEG 3350, 10 mM MgCl2, 0.1 M sodium acetate,
pH 5.2 or 7.0, at 4C for 3 days. Cryosolvent was prepared by adding 33%
ethylene glycol into the soaking buffer. Diffraction data were collected using
APS beamlines 22-BM and 22-ID. All data were processed with the program
HKL2000. The structure was determined using rigid body and direct Fourier
synthesis, and refinedwith theequivalent andexpanded test sets. The structure
was further manually rebuilt with COOT and refined with PHENIX and REFMAC
from the CCP4 package. Ligand topology and parameter files were prepared
using the PRODRG server. The molecular graphics representations were
preparedwith the programPyMol (Schro¨dinger). The 2D ligand-protein interac-
tion diagrams were generated by LigPlot+.
Enzyme Assays
HPLC was used to assay [3H]InsP6 phosphorylation by human PPIP5K2
KD or
human IP6K2 in 100 ml buffer containing 50 mM KCl, 20 mM HEPES pH 7.0,
7 mM MgSO4, 5 mM ATP, and 1 mM EDTA (for IP6K2, [MgSO4] was 12 mM
and [ATP] was 10 mM). The initial InsP6 concentration was either 500 nM,
70 nM, or 40 nM. Various concentrations of 2,5-di-O-Bn-InsP4 were present
as indicated. Radioactivity was assessed using an in-line Flo1 detector. The
ADP-driven dephosphorylation of 100 nM 1,5-[PP]2-InsP4 by PPIP5K2
KD
was usually determined by a luminescence-based assay of ATP accumulation
(Riley et al., 2012; Weaver et al., 2013). The IC50 values were determined using
GraphPad Prism v6.02 (n R 3). In some experiments, 1,5-[PP]2-[
3H]InsP4
dephosphorylation by PPIP5K2KD was assayed in 50 ml buffer containing
50 mM KCl, 20 mM HEPES pH 7.0, 7 mM MgSO4, 5 mM ADP, 1 mM EDTA.
Reactions were then quenched, neutralized, and analyzed with HPLC using
a Partisphere SAX column (Weaver et al., 2013); 1 ml fractions were collected
for liquid scintillation spectrometry. The ATPase activity of PPIP5K2KD
(10–270 mg/ml) was assayed from Pi release following incubation at 37C for
120–180 min in 20 ml reaction mixtures containing 20 mM Tris/HCl, pH 7.5,
10 mM ATP, 100 mM KCl, 0.1 mM EDTA, and 13 mM MgCl2.
Statistical Analysis
In the figures, error bars represent SEs from three experiments.
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